Protect your patients from exacerbations

Exacerbation reduction with NUCALA

Proven protection from exacerbations

Trial 2 (32 weeks)1

Trial 2 exacerbation reduction graph

Primary endpoint at Week 32.

SOC=standard of care.

View Trial 2 study design 

Exacerbations in real-world study2

71% and 74% reduction in exacerbations
71% and 74% reduction in exacerbations

Results are descriptive.

*1-year analysis model. †2-year analysis model.

Real-world study limitations: 2-year, single-arm, prospective, observational cohort study.

Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.

View real-world study design

Trend of greater reduction in exacerbations seen at higher blood eosinophil levels

Trial 22

Up to

Exacerbation post hoc analysis per blood baseline blood eosinophil levels

75%

reduction

in exacerbations in patients
with ≥500 cells/µL vs placebo‡

Post hoc analysis. Results are descriptive.

‡NUCALA+SOC (n=66): 0.54/year, placebo+SOC (n=66): 2.11/year; rate ratio vs placebo at Week 32: 0.25 (95% CI: 0.15, 0.43).

Trial 2: This analysis assessed the relationship between baseline blood eosinophil counts and efficacy outcomes after treatment.2,3

View Trial 2 study design 

Reduction in exacerbations requiring hospitalization/ED visit

Demonstrated protection in Trial 21

Trial 2 hospital/ED visit exacerbation

61%

reduction

vs placebo in
exacerbations requiring
hospitalization/ED visit

NUCALA+SOC: 0.08/year, placebo+SOC: 0.20/year; P=0.02.
Secondary endpoint at Week 32.

View Trial 2 study design 

Exacerbations requiring hospitalization/ED visit in real-world study2

76% and 79% reduction in exacerbations
76% and 79% reduction in exacerbations

Secondary objective. Results are descriptive.

Secondary objective. Results are descriptive.

§1-year analysis model. ll2-year analysis model.

Real-world study limitations: 2-year, single-arm, prospective, observational cohort study.

Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.

ED=emergency department.

 

View real-world study design

Exacerbations requiring hospitalization: clinical and real-world data

Trial 2: 69% reduction in exacerbations requiring hospitalization vs placebo. NUCALA, 0.03 vs placebo, 0.10, rate ratio: 0.31 (95% CI, 0.11, 0.91)1. Results are descriptive.
 

Real-world study: 73% reduction in exacerbations requiring hospitalization. NUCALA 2-year post-exposure (N=820) 0.12 vs NUCALA 1-year pre-exposure (N=821) 0.45; rate ratio 0.27 (95% CI, 0.21, 0.33).2 Secondary objective. Results are descriptive.

1-year pre-exposure (baseline) based on 1-year analysis model.2

89%
of patients had zero exacerbations requiring hospitalization
at 2 years post-exposure vs 76% 1-year pre-exposure2

89%
of patients had zero exacerbations
requiring hospitalization at
2-year post-exposure vs
76% 1-year pre-exposure2

Results are descriptive.

Real-world study limitations: 2-year, single-arm, prospective, observational cohort study.  

Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.

View real-world study design

Next: OCS reduction

Red checklist icon

Access & support

Request a Rep

Request a Rep